Motilium: Expert Relief for Gastric Motility Disorders
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.02 | $40.17 (0%) | 🛒 Add to cart |
| 20 | $2.26 | $80.33 $45.19 (44%) | 🛒 Add to cart |
| 30 | $1.67 | $120.50 $50.21 (58%) | 🛒 Add to cart |
| 60 | $0.92 | $240.99 $55.23 (77%) | 🛒 Add to cart |
| 90 | $0.67 | $361.49 $60.25 (83%) | 🛒 Add to cart |
| 120 | $0.54 | $481.99 $65.27 (86%) | 🛒 Add to cart |
| 180 | $0.39 | $722.98 $70.29 (90%) | 🛒 Add to cart |
| 270 | $0.32 | $1084.47 $85.35 (92%) | 🛒 Add to cart |
| 360 | $0.26
Best per pill | $1445.97 $95.39 (93%) | 🛒 Add to cart |
Synonyms
| |||
Motilium (domperidone) is a dopamine antagonist medication specifically formulated to enhance gastric motility and alleviate upper gastrointestinal symptoms. It is clinically indicated for the management of nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying. By acting on chemoreceptor trigger zones and gastric smooth muscle, it facilitates coordinated peristalsis without central sedative effects. This makes it a preferred agent in both acute and chronic dyspeptic conditions where prokinetic intervention is warranted.
Features
- Active ingredient: Domperidone 10mg per tablet
- Pharmacological class: Dopamine D2 and D3 receptor antagonist
- Formulation: Oral tablets with rapid disintegration properties
- Onset of action: Typically within 30–60 minutes post-administration
- Half-life: Approximately 7–9 hours in adults
- Excretion: Primarily hepatic metabolism via CYP3A4, fecal elimination
Benefits
- Effectively reduces episodes of nausea and vomiting by blocking dopamine receptors in the chemoreceptor trigger zone
- Accelerates gastric emptying and improves gastroduodenal coordination, relieving postprandial fullness
- Minimizes symptoms of functional dyspepsia, including early satiety and upper abdominal bloating
- Lacks significant penetration of the blood-brain barrier, reducing risk of extrapyramidal side effects
- Supports continued nutritional intake by mitigating meal-related discomfort
- May assist in managing gastroesophageal reflux symptoms when standard therapy is insufficient
Common use
Motilium is commonly prescribed for symptomatic relief of nausea and vomiting of various etiologies, including those related to gastroenteritis, medication side effects, or functional gastrointestinal disorders. It is also used off-label in some jurisdictions to stimulate lactation, though this application requires careful risk-benefit assessment. Clinicians frequently recommend it for patients experiencing gastroparesis secondary to diabetes, post-operative states, or idiopathic causes.
Dosage and direction
The standard adult dosage is one 10mg tablet taken orally three to four times daily, preferably 15–30 minutes before meals and at bedtime. Maximum daily intake should not exceed 30mg (or 0.75mg/kg in pediatric populations, where approved). Tablets should be swallowed whole with water; they are not designed for chewing or crushing. Duration of therapy depends on symptom resolution, but extended use beyond 4 weeks requires reevaluation.
Precautions
Use with caution in patients with hepatic impairment, as domperidone is extensively metabolized by the liver. Electrolyte imbalances (particularly hypokalemia or hypomagnesemia) may increase the risk of arrhythmias. Avoid concomitant use with other QT-prolonging agents. Elderly patients and those with underlying cardiac conditions should undergo baseline and periodic ECG monitoring if prolonged therapy is necessary.
Contraindications
Motilium is contraindicated in patients with known hypersensitivity to domperidone or any excipients in the formulation. It must not be used in individuals with pre-existing prolongation of cardiac conduction intervals, especially QTc >450ms in adults or age-adjusted prolongation in children. Severe hepatic impairment, prolactinoma, and concomitant use of strong CYP3A4 inhibitors are also absolute contraindications.
Possible side effects
Common adverse reactions include dry mouth, headache, and abdominal cramps. Less frequently, patients may experience diarrhea, nervousness, or drowsiness. Elevated prolactin levels may lead to galactorrhea, gynecomastia, or menstrual irregularities. Although rare, serious side effects include ventricular arrhythmias, including torsades de pointes, particularly in predisposed individuals or with overdose.
Drug interaction
Domperidone is primarily metabolized by CYP3A4; coadministration with potent inhibitors of this enzyme (e.g., ketoconazole, erythromycin, clarithromycin, ritonavir) significantly increases plasma concentrations and is contraindicated. Concurrent use with other prokinetic agents may amplify gastrointestinal effects. Anticholinergic drugs may antagonize Motilium’s therapeutic benefits.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one.
Overdose
Symptoms of overdose may include drowsiness, disorientation, extrapyramidal reactions, or cardiac effects such as QTc prolongation. There is no specific antidote; management is supportive and includes gastric lavage (if recent ingestion) and ECG monitoring. Symptomatic treatment for arrhythmias or extrapyramidal symptoms should be administered as clinically indicated.
Storage
Store at room temperature (15–30°C) in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and educated patients and should not replace personalized medical advice. Always consult a qualified healthcare provider for diagnosis, dosing, and treatment recommendations tailored to individual health status and concurrent medications.
Reviews
Clinical studies and meta-analyses consistently demonstrate Motilium’s efficacy in reducing nausea and vomiting scores compared to placebo. In a randomized controlled trial involving 553 patients with diabetic gastroparesis, domperidone significantly improved gastric emptying times and symptom severity. Post-marketing surveillance confirms a favorable benefit-risk profile when used within recommended guidelines, though cardiovascular monitoring remains advised in at-risk populations.